Carmat has developed the first auto-regulating, bioprosthetic artificial heart able to mimic the natural physiology of the human heart like never before.
In 2017, Carmat has entered into the active strategic market access deployment aimed at providing end-stage heart failure patients with an alternative solution to heart transplantation.
In 2019 they will get the market.
WiSNAM Value Proposition
- Digitalization and remote connection of their Total Artificial Heart (TAH)
- Bridge to innovative service therapy for implanted patients
- Predict heart diseases through smart algorithms and big data technologies
WiSNAM has been selected to design a new gateway for the extraction of data from the controller of the TAH. The project has started in mid 2018 and the solutions we are designing will be ready for clinical trials at the end of 2018.
A fast-growing, high-potential market with more than 150,000 patients suffering from terminal biventricular heart failure each year. Only 5.000 grafts available per year.